TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study
2024 · BMC Cancer · 12 citations
https://doi.org/10.1186/s12885-024-12484-3
X
Xingzhi Li
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
14
Papers
433
Citations
8
h-index
8
i10-index
Xingzhi Li is an academic researcher from University of Nebraska–Lincoln. The author has contributed to research in topics: Hepatocellular Carcinoma Treatment and Prognosis & Pancreatic and Hepatic Oncology Research & Renal cell carcinoma treatment. The author has an h-index of 8, co-authored 12 publications.
ORCID: 0000-0002-2784-4575Papers by this author
worksCritical contributions of protein cargos to the functions of macrophage-derived extracellular vesicles
2023 · Journal of Nanobiotechnology · 11 citations
https://doi.org/10.1186/s12951-023-02105-9
Honey vesicle-like nanoparticles protect aged liver from non-alcoholic steatohepatitis
2024 · Acta Pharmaceutica Sinica B · 11 citations
https://doi.org/10.1016/j.apsb.2024.05.002
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat